|
1) Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-33
|
|
|
|
2) Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995; 332: 1589-93
|
|
|
|
|
|
3) Lindsay R, Bush TL, Grady D, et al. Therapeutic controversy: Estrogen replacement in menopause. J Clin Endocrinol Metab. 1996; 81: 3829-38
|
|
|
|
|
|
4) Stahlberg C, Pederson AT, Lynge E, et al. Hormone replacement therapy and risk of breast cancer: the role of progestins. Acta Obstet Gynecol Scand. 2003; 82: 335-44
|
|
|
|
|
|
5) Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999; 281: 2189-97
|
|
|
|
|
|
6) 骨粗鬆症の予防と治療ガイドライン作成委員会(代表 折茂 肇)編. 骨粗鬆症の予防と治療ガイドライン2006年版. 東京: ライフサイエンス出版; 2006. p. 88-94
|
|
|
|
|
|
7) Ettinger B, Black DM, Mitlak BH, et al. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999; 282: 637-45
|
|
|
|
|
|
8) Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med. 2002; 162: 1140 -3
|
|
|
|
|
|
9) Delmas PD, Ensrud KE, Adachi JD, et al. For the Multiple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reducetion in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002; 87: 3609-17
|
|
|
|
|
|
10) Morii H, Ohashi Y, Tatetani Y, et al. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int. 2003; 14: 793-800
|
|
|
|
|
|
11) Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone. 2003; 33: 522-32
|
|
|
|
|
|
12) Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement. 2000; 17: 1-45 (http://www.consensus.nih.gov/cons/111/111_statement.htm)
|
|
|
|
|
|
13) Burr DB. Effects of bone active agents on bone quality. Osteoporos Int. 2002; 13: S73-4
|
|
|
|
|
|
14) Hisamoto K, Ohmichi M, Kurachi H, et al. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem. 2001; 276: 3459 -67
|
|
|
|
|
|
15) Hisamoto K, Ohmichi M, Kanda Y, et al. Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY 117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells. J Biol Chem. 2001; 276: 47642-9
|
|
|
|
|
|
16) Takahashi K, Ohmichi M, Yoshida M, et al. Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. J Endocrinol. 2003; 178: 319-29
|
|
|
|
|
|
17) Mori-Abe A, Tsutsumi S, Takahashi K, et al. Estrogen and raloxifene induce apoptosis by activating p38 mitrogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J Endrocrinol. 2003; 178: 417-26
|
|
|
|
|
|
18) Ohmichi M, Kanda Y, Hisamoto K, et al. Rapid changes of flow-mediated dilatation after surgical menopause. Maturitas. 2003; 44: 125-31
|
|
|
|
|
|
19) Takahashi K, Mori-Abe A, Takata K, et al. Raloxifene improves the ovariectomy-induced impairment in endothelium-dependent vasodilation. Menopause. 2007; 14: 656-61
|
|
|
|
|
|
20) Barrett-Connor E, Grady D, Sashegyi A, et al; MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002; 287: 847-57
|
|
|
|
|
|
21) Barrett-Connor E, Mosca L, Collins P, et al; Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006; 355: 125-37
|
|
|
|
|
|
22) Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003; 361: 296-300
|
|
|
|
|
|
23) Martino S, Cauley JA, Barrett-Connor E, et al; CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004; 96: 1751-61
|
|
|
|
|
|
24) Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifene vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifene and Raloxifene (STAR) P-2 trial. JAMA. 2006; 295: 2727-41
|
|
|
|
|
|
25) Jirecek S, Lee A, Pavo I, et al. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril. 2004; 81: 132-6
|
|
|
|
|
|
26) Palomba S, Sammartino A, Di Carlo C, et al. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril. 2001; 76: 38-43
|
|
|
|
|
|
27) Lindsay R, Bush TL, Grady D, et al. Therapeutic controversy: Estrogen replacement in menopause. J Clin Endocrinol Metab. 1996; 81: 3829- 38
|
|
|
|
|
|
28) Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol. 1999; 93: 558-65
|
|
|
|
|
|
29) Goldstein SR, Scheele WH, Rajagopalan SK, et al. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol. 2000; 95: 95-103
|
|
|
|
|
|
30) Riggs BL, Hartmann LC. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. N Engl J Med. 2003; 348: 618-29
|
|
|
|
|